REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 — Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. To order the test, physicians may contact […]
REHOVOT, Israel and JERSEY CITY, New Jersey and PHILADELPHIA, December 22 — Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today the commercial availability of its second diagnostic test, miRview(TM) mets. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. The test identifies 25 different tumor […]
EMERYVILLE, Calif., Dec 18, 2008 — ProGenTech Limited, a life science and molecular diagnostics company based in Shanghai, China and the San Francisco Bay Area has signed a collaboration agreement with the China CDC to create a joint laboratory that will focus on developing next generation molecular diagnostic systems and assays. Under the terms of […]
Company Reaffirms Its Regulatory Stance in Offering HerScan as a Laboratory Developed Test (LDT) in Response to Genentech FDA Citizen Petition Filing MUKILTEO, Wash., Dec. 18, 2008 — CombiMatrix Corporation (NasdaqGM:CBMX – News) today announced that expanded study results on the company’s HerScan(tm) array comparative genomic hybridization (array CGH) test demonstrated 97% concordance with fluorescent […]
Total acquisition price will be $215 million Acquisition will expand Abbott’s position in molecular diagnostics for infectious disease CARLSBAD, Calif. and ABBOTT PARK, Ill., Dec. 17 — Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Abbott (NYSE: ABT) announced today that Abbott has exercised its option to purchase the remaining equity ownership in Ibis Biosciences, Inc., an […]
Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded international patent protection for a break-through technology able to accelerate the detection of highly personal variations in genetic sequences. These genetic variations can identify an individual’s risks for a broad range of disorders, such as Alzheimer’s disease and coronary artery […]
ProScan Array is First Genome-Based Test to Introduce Genomic Pathology to Prostate Cancer MUKILTEO, Wash., Dec 16, 2008 — CombiMatrix Corporation today announced the introduction of the first prostate cancer array-based test. Known as the ProScan(tm) test, it complements the company’s growing portfolio of array-based diagnostic tests. The ProScan test is based on key peer-reviewed […]
BioTrove, Inc. today announced its collaboration with Children’s Hospital of Eastern Ontario (CHEO) researchers in the evaluation of BioTrove’s OpenArray® technology as a system to detect and monitor respiratory infectious disease pathogens in children. The study combines BioTrove’s OpenArray nanofluidic polymerase chain reaction (PCR) technology platform with CHEO’s clinical and molecular biology expertise for rapid, […]
Exiqon announces launch of first molecular diagnostic test for colon cancer recurrence based on miRNA Exiqon A/S, NASDAQ OMX Copenhagen (“EXQ”), today announced the launch of its first molecular diagnostic test based on miRNA. The miRNA-based prognostic test will help identify stage II colon cancer patients who may be at significantly higher risk for recurrence […]
HUNTINGTON BEACH, California and AMSTERDAM, December 12 — Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)’s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van ‘t Veer, from the Netherlands Cancer Institute, presented the data at the 2008 San Antonio Breast Cancer Symposium (SABCS) during the session Molecular […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
